FDA recall D-0032-2025 · initiated Oct 10, 2024
May cause temporary or medically reversible harm; low probability of serious harm.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.